RED Specialist prescribing only For information on Malignant Disease and Immunosuppression, please follow BNF Chapter 8 at the end of this ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
RED Specialist prescribing only
For information on Malignant Disease and Immunosuppression, please
follow BNF Chapter 8 at the end of this document.
THERAPEUTIC
GENERIC NAME BRAND NAME
INDICATION
Adefovir dipivoxil (Hepsera®) Chronic hepatitis B
Acitretin (Neotigason®) Psoriasis
Alitretinoin (Toctino®) Severe chronic hand
eczema in adults
Anagrelide (Xagrid®) Essential
thrombocythaemia
Anti-TNF–α drugs and
cytokine modulators
- abatacept (Orencia®)
- adalimumab (Humira®)
- anakinra (Kineret®)
- belimumab (Benlysta®)
All indications
- certolizumab pegol (Cimzia®)
- etanercept (Enbrel®)
- golimumab (Simponi®)
- infliximab (Remicade®)
- rituximab (Generic)
- tocilizumab (RoActemra®)
Antivirals for HIV
infections.
1.Nucleoside reverse
transcriptase inhibitors
- abacavir (Ziagen®/Kivexa®/Trizivir®)
- didanosine (Videx®)
- emtricitabine (Emtriva®)
- lamivudine (Epivir®/Zeffix®)
- stavudine (Zerit®)
- tenofovir (Viread®/Truvada®/Atripla®/
Eviplear®)
- zidovudine (Zidovudine®/Retrovir®/
Combivir®) HIV infection
2.Protease inhibitors
- atazanavir (Reyataz®)
- darunavir (Prezista®)
- fosamprenavir (Telzir®)
- indinavir (Crixivan®)
- lopinavir (Kaletra®)
- nelfinavir (Viracept®)
- ritonavir (Norvir®)
- saquinavir (Invirase®)
- tipranavir (Aptivus®)
3.Non-nucleoside reverse
transcriptase inhibitors
1
RED TRAFFIC LIGHT LIST. May 2021- efavirenz (Sustiva®)
- etravirinr (Intelence®)
- nevirapine (Viramune®)
- rilpivirine (Edurant®)
4.Other antiretrovirals
- enfuvirtide (Fuzeon®)
- maraviroc (Celsentri®)
- raltegravir (Isentress®)
Apraclonidine (Iopidine®)
Asenapine (Sycrest®) Moderate to severe
manic episodes in
bipolar 1 disorder in
adults
Avelumab with axitinib Untreated advanced
renal cell carcinoma
Becaplermin Gel (Regranex ®) Adjunct treatment of
No license in this country full-thickness,
neuropathic, diabetic
ulcers
Boceprevir (Victrelis ®) Chronic hepatitis C
Botulinum toxin (Botox, Dysport ®) All indications
Buprenorphine oral (Espranor®) All indications
lyophilisate
Cannabis-based Defined approved
medicinal preparations indications within
paediatrics and
neurology
Cidofovir (Vistide®) Cytomegalovirus
(CMV) retinitis in AIDS
Cinacalcet (Mimpara ®) Secondary
hyperparathyroidism in
patients with end-
stage renal disease
Clozapine (Clorazil®) Schizophrenia
Colchicine (Generic) Pericarditis caused by
systemic inflammatory
diseases and post-
cardiac injury
syndromes
Dapagliflozin (Forxiga®) Type-1 Diabetes
Deferasirox, deferiprone, (Exjade®, Ferriprox®, Treatment of iron
desferrioxamine mesilate Desferal ®) overload
Dexamethasone (Generic) Treatment of COVID-
19 infection
Entecavir (Baraclude®) Chronic hepatitis B
Ferric maltol (Feraccru®) Iron deficiency in
adults with
2
RED TRAFFIC LIGHT LIST. May 2021inflammatory bowel
disease
Filgrastim (Neupogen®) Neutropenia
Fondaparinux (Arixtra®) VTE prophylaxis and
heparin-induced
thrombocytopenia
Foscarnet (Foscavir®) CMV retinitis in AIDS
Fremanezumab (Ajovy®) Preventing chronic
migraine
Galcanezumab (Emgality®) Preventing migraine
Ganciclovir (Cymevene®) Life and sight
threatening
cytomegalovirus
infections
Hylan (Synvisc ®) Osteoarthritis
Ibandronic acid I.V (Bonviva ®) Osteoporosis in
postmenopausal
women
Isotretinoin (Roaccutane ®) Acne
IVF intranasal and
In-vitro fertilisation
injectable drugs
Ketamine oral solution (Unlicensed special ®) Unlicensed use for the
relief of pain in
palliative care patients
and for the
management of
chronic pain
Lenograstim (Granocyte®) Neutropenia
Linaclotide (Constella®) IBS - Constipation
Linezolid (Zyvox®) Antibiotic
Liothyronine Hypothyroidism
Liraglutide (Saxenda®) Managing overweight
and obesity
Metolazone (Unlicensed special) Heart failure, oedema,
hypertension
Moviprep® (Moviprep®) Preparation for
endoscopy – hospital to
supply to patients in
advance of endoscopy
appointment
Palivizumab (Synagis®) Prevention of serious
lower respiratory
infection caused by
RSV
Patiromer (Veltassa®) Hyperkalaemia
3
RED TRAFFIC LIGHT LIST. May 2021Quinagolide (Norprolac®) Hyperprolactinaemia
Ribavirin (Rebetol®) Severe respiratory
sybcytial virus
bronchiolitis
Sertindole (Serdolect®) Schizophrenia
Siponimod (Mayzent®) Multiple sclerosis
Sotagliflozin (Not licensed in UK) Type-1 diabetes
Telaprevir (Incivo®) Chronic hepatitis C
Telbivudine (Sebivo®) Chronic hepatitis B
Upadacitinib (RINVOQ®) Rheumatoid arthritis
Valganciclovir (Valcyte®) Prophylaxis of CMV
(and treatment of CMV
– unlicensed)
BNF Chapter 8. Malignant Disease and Immunosuppression.
GENERIC NAME BRAND NAME (not exhaustive)
Abiraterone acetate (Zytiga®)
Aldesleukin (Proleukin®)
Alemtuzumab (MabCampath®)
Amsacrine (Amsidine®)
Antithymocyte immunoglobulin (rabbit) (Thymoglobuline®)
Atezolizumab (Tecentriq®)
Arsenic trioxide (Trisenox®)
Azacitidine (Vidaza®)
Bacillus Calmette-Guerin (BCG) (ImmuCyst®/OncoTICE®)
Basiliximab (Simulect®)
Belatacept (Nulojix®)
Bendamustine (Levact®)
Bevacizumab (Avastin®)
Bexarotene (Targretin®)
Bleomycin
Bortezomib (Velcade®)
Brigatinib (Alunbrig®)
Busulfan (Myleran®
Busilvex®)
Canakinumab (Ilaris®)
Capecitabine (Xeloda®)
Caplacizumab (Cablivi®)
Carfilzomib (Kyprolis®)
Carmustine (Gliadel®)
Catumaxomab (Removab®)
4
RED TRAFFIC LIGHT LIST. May 2021Cetuximab (Erbitux®)
Chlorambucil (Leukeran®)
Cladribine (Leustat®)
(Litak®)
Clofarabine (Evoltra®)
Crisantaspase (Erwinase®)
Cyclophosphamide
Cytarabine (DepoCyte®)
Dacarbazine
Dactinomycin
Darolutamide (NUBEQA®)
Daunorubicin (DaunoXome®)
(Caelyx®)
Doxorubicin hydrochloride
(Myocet®)
Encorafenib (Braftovi®)
Epirubicin (Generic and Pharmorubicin®)
Eribulin (Halaven®)
Estramustine phosphate (Estracyt®)
Etoposide (Etopophos®)
(Vepesid®)
Fingolimod (Gilenya®)
Fludarabine phosphate (Fludara®)
Fluorouracil (injection)
Fulvestrant (Faslodex®)
Gemcitabine (Gemzar®)
Gimeracil
Glatiramer acetate (Copaxone®)
Histamine Dihydrochloride (Ceplene®)
Histrelin (Vantas®)
Idarubicin (Zavedos®)
Ifosfamide
Interferon alfa
- Interferon alfa (Intron A®)
(Pegasys®/ViraferonPeg®)
- Peginterferon alfa
Interferon beta
- Interferon beta-1a (Avonex®/Rebif®)
- Interferon beta-1b (Betaferon®/Extavia®)
Interferon Gamma-1b (Immukin®)
Ipilimumab (Yervoy®)
Isatuximab (SARCLISA®)
Lenalidomide
Lomustine
5
RED TRAFFIC LIGHT LIST. May 2021Melphalan (Alkeran®)
Mifamurtide (Mepact®)
Mitomycin (Mitomycin C Kyowa®)
Mitotane (Lysodren®)
Mitoxantrone (Onkotrone®)
Natalizumab (Tysabri®)
Nelarabine (Atriance®)
Nivolumab (OPDIVO®)
Obinutuzumab (Gazyvaro®)
Ofatumumab (Arzerra®)
Osimertinib (TAGRISSO®)
Oteracil
Panitumumab (Vectibix®)
Pembrolizumab (KEYTRUDA®)
Pemetrexed (Alimta®)
Pentostatin (Nipent®)
Platinum compounds
- Carboplatin
- Cisplatin
- Oxaliplatin
Polatuzumab vedotin (Polivy®)
Pomalidomide (Imnovid®)
Porfimer sodium
Procarbazine
Protein kinase inhibitors
- Dasatinib (Sprycel®)
- Erlotinib (Tarceva®)
- Everolimus (Afinitor®/Votubia®)
- Gefitinib (Iressa®)
- Imatinib (Glivec®)
- Lapatinib (Tyverb®)
- Nilotinib (Tasigna®)
- Pazopanib (Votrient®)
- Sorafenib (Nexavar®)
- Sunitinib (Sutent®)
- Temsirolimus (Torisel®)
- Vandetanib (Caprelsa®)
- Vemurafenib (Zelboraf®)
Thiotepa (Tepadina®)
Treosulfan
Raltitrexed (Tomudex®)
Rituximab (MabThera®)
Taxanes
- Carbazitaxel (Jevtana®)
6
RED TRAFFIC LIGHT LIST. May 2021- Docetaxel (Generic and Taxotere®)
- Paclitaxel (Generic and Abraxane®)
Tegafur with and
Tegafur with Uracil (Uftoral® )
Temoporfin
Temozolomide
Thalidomide
Tioguanine (Lanvis®)
Topoisomerase I inhibitors
- Irinotecan Hydrochloride (Generic and Campto®)
- Topotecan (Generic and Hycamtin®)
Trabectedin (Yondelis®)
Trastuzumab (Herceptin®)
Tretinoin (Vesanoid®)
Venetoclax (Venclyxto®)
Vinblastine sulfate (Velve®)
Vincristine sulfate (Oncovin®)
Vindesine sulfate (Eldisine®)
Vinflunine (Javlor® )
Vinorelbine (Navelbine®)
Formulary Traffic Light List RED
Date ratified by D&T Committee May 2013
1st Amendment August 2013. Linaclotide included
Ratified by D&T August 2013
2nd Amendment October 2013.
Lisdexamfetamine mesilate and Asenapine included
Ratified by D&T October 2013
3rd Amendment March 2014.
Lisdexamfetamine mesilate removed.
Ratified by D&T March 2014
Next Review Date March 2016
4th Amendment April 2014
Apraclonidine (Iopidine®) included
Ratified by D&T April 2014
Next Review Date April 2016
5th Amendment October 2018
Ulipristal (Esmya®) included
Ratified by D&T October 2018
Next Review Date October 2020
6th Amendment October 2019
Dapagliflozin (Forxiga®) included
Next Review Date October 2020
7th Amendment August 2020
Ulipristal (Esmya®) removed (license suspension)
Metolazone indications included
Colchicine included
Dexamethasone included
Sotagliflozin included
Patiromer included
Moviprep® included
Ratified by D&T August 2020
Next review date August 2021
7
RED TRAFFIC LIGHT LIST. May 20218th Amendment October 2020
Buprenorphine oral lyophilisate included
Fondaparinux included
Ratified by D&T October 2020
Next review date October 2021
9th Amendment November 2020
Avelumab with axitinib included
Cannabis-based medicinal preparations included
Liothyronine included
Additions approved by MSEMOC October 2020
Next review date November 2021
10th Amendment May 2021 – additions
Atezolizumab Liraglutide
Brigatinib Nivolumab
Caplacizumab Obinutuzumab
Carfilzomib Osimertinib
Darolutamide Pembrolizumab
Encorafenib Polatuzumab vedotin
Ferric maltol Pomalidomide
Fremanezumab Siponimod
Galcanezumab Upadacitinib
Isatuximab Venetoclax
Chapter 8 sub-sections combined and alphabetised.
Additions approved by MSEMOC December 2020, February 2021
Next review date May 2022
8
RED TRAFFIC LIGHT LIST. May 2021You can also read
